Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer

Markus Diefenhardt; Ethan B Ludmir; Ralf-Dieter Hofheinz; Michael Ghadimi; Bruce D Minsky; Claus Rödel; Emmanouil Fokas

doi:10.1001/jamaoncol.2019.5102

Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer

JAMA Oncol. 2020 Feb 1;6(2):294-296. doi: 10.1001/jamaoncol.2019.5102.

Authors

Markus Diefenhardt^{1

2}, Ethan B Ludmir³, Ralf-Dieter Hofheinz⁴, Michael Ghadimi⁵, Bruce D Minsky³, Claus Rödel^{1

2

6}, Emmanouil Fokas^{1

2

6}

Affiliations

¹ Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany.
² Frankfurt Cancer Institute, Frankfurt, Germany.
³ Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
⁴ Department of Medical Oncology, University Hospital Mannheim, Heidelberg University, Heidelberg, Germany.
⁵ Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
⁶ German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), Partner Site Frankfurt am Main, Frankfurt, Germany.

Abstract

This pooled analysis of data from phase 3 randomized clinical trials assesses the association of sex with toxic effects, treatment adherence, surgical procedures, and long-term outcomes after standard multimodal treatment in patients with rectal cancer.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Aged
Antimetabolites, Antineoplastic / adverse effects*
Chemoradiotherapy, Adjuvant
Female
Fluorouracil / adverse effects*
Humans
Male
Medication Adherence*
Middle Aged
Prognosis
Rectal Neoplasms / mortality
Rectal Neoplasms / therapy*
Sex Characteristics*

Substances

Antimetabolites, Antineoplastic
Fluorouracil